Healthcare Services

Chemotherapy-Induced Anemia Market Outlook (2026–2030): Growth Drivers and Projections

April 20, 2026April 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Chemotherapy-Induced Anemia Market Between 2026 And 2030?

The chemotherapy-induced anemia market has demonstrated significant expansion in recent years. This market is set to expand from $2.81 billion in 2025 to $3.03 billion in 2026, progressing at a compound annual growth rate (CAGR) of 7.7%. The growth observed in previous periods was largely a result of the increasing adoption of intensive chemotherapy regimens, the growing incidence of treatment-related anemia, the establishment of more oncology treatment centers, enhanced access to blood transfusion services, and the provision of supportive cancer care therapies.

The market for chemotherapy-induced anemia is projected to experience robust expansion over the coming years. This market is anticipated to reach $4.13 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.1%. Several factors are expected to drive this growth during the forecast period, including a heightened demand for long-lasting anemia treatments, a greater emphasis on reducing transfusion dependency, the broadening of personalized oncology care, an increase in the uptake of home-based treatment approaches, and ongoing innovations in anemia management medications. Key trends foreseen during this period involve a rising acceptance of erythropoiesis-stimulating agents, the expanded implementation of individualized anemia management plans, a growing inclination towards early intervention strategies, the development of more outpatient settings for anemia treatment, and an intensified commitment to improving patients’ quality of life.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

What Significant Factors Are Influencing The Chemotherapy-Induced Anemia Market Expansion?

The widespread incidence of cancer and anemia is anticipated to drive the future expansion of the chemotherapy-induced anemia market. Cancer is defined as a condition where cells multiply uncontrollably and spread to different parts of the body. Both cancer itself and chemotherapy-induced anemia (CIA) are common among cancer patients undergoing aggressive chemotherapy, with or without radiation therapy. Medications designed to treat chemotherapy-induced anemia work by stimulating the bone marrow to produce red blood cells. As an illustration, Cancer Research UK, an independent cancer research organization based in the UK, reported in 2023 that the incidence of head and neck cancer in the UK is projected to increase by 3% between 2023 and 2025, with deaths from these cancers expected to rise by 12% during the same timeframe. Thus, the significant prevalence of cancer and anemia is a key factor propelling the growth of the chemotherapy-induced anemia market.

How Is The Chemotherapy-Induced Anemia Market Categorized Across Its Segment Groups?

The chemotherapy-induced anemia market covered in this report is segmented –

1) By Anemia: Mild Anemia, Moderate Anemia, Severe Anemia, Life-Threatening Anemia

2) By Treatment Type: RBC (Red Blood Cells) Transfusion, Erythropoiesis-Stimulating Agents (ESAs), Iron Supplementation

3) By End-User: Hospitals, Ambulatory Surgical Centers, Multispecialty Clinics, Cancer Research Centers, Cancer Rehabilitation Centers

Subsegments:

1) By Mild Anemia: Hemoglobin Levels 10-12 Grams Per Deciliter (g/dL), Symptomatic Treatments

2) By Moderate Anemia: Hemoglobin Levels 8-10 Grams Per Deciliter (g/dL), Erythropoiesis-stimulating Agents (ESAs), Blood Transfusion Management

3) By Severe Anemia: Hemoglobin Levels 6.5-8 Grams Per Deciliter (g/dL), Intensive ESA Treatments, Frequent Blood Transfusions

4) By Life-Threatening Anemia: Hemoglobin Levels Below 6.5 Grams Per Deciliter (g/dL), Emergency interventions, Critical Care And Monitoring

What Trends Are Affecting The Direction Of The Chemotherapy-Induced Anemia Market?

Leading companies in the chemotherapy-induced anemia market are concentrating on advancing technologies, such as Ojjaara (momelotinib), to bolster treatment options and improve patient outcomes for those suffering from anemia related to cancer therapies. The designation ‘Ojjaara’ is derived from ‘Ojaara,’ which signifies a connection to concepts of healing or wellness. For instance, in September 2023, Ojjaara (momelotinib) was developed by GSK (GlaxoSmithKline), an England-based company; this development underscores the drug’s role as a treatment for myelofibrosis, especially in patients presenting with anemia. Ojjaara (momelotinib) serves as an innovative treatment for myelofibrosis patients experiencing anemia, operating by inhibiting key pathways to enhance blood counts, elevate quality of life, and decrease the necessity for blood transfusions, establishing it as the initial and sole therapy specifically indicated for this condition.

Which Firms Are Influencing Competition In The Chemotherapy-Induced Anemia Market?

Major companies operating in the chemotherapy-induced anemia market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Baxter International Inc., Fresenius Kabi AG, Biocon Ltd., Vifor Pharma Group, Pharmacosmos A/S, Daiichi Sankyo Company Limited, Bayer AG, Akebia Therapeutics Inc, Otsuka Pharmaceutical Co Ltd, Zydus Lifesciences Ltd, Viatris Inc, Shield Therapeutics plc, Keros Therapeutics Inc

Get The Full Chemotherapy-Induced Anemia Market Report:

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

Which Region Accounts For The Largest Portion Of The Chemotherapy-Induced Anemia Market?

North America was the largest region in the chemotherapy-induced anemia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemotherapy-induced anemia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Chemotherapy-Induced Anemia Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

Browse Through More Reports Similar to the Global Chemotherapy-Induced Anemia Market 2026, By The Business Research Company

Chemotherapy Induced Myelosuppression Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-myelosuppression-treatment-global-market-report

Anemia And Other Blood Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Chemotherapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795